Dr. Matthew H. Kulke Talks About Telotristat Etiprate Benefitting Carcinoid Syndrome Patients
Matthew H. Kulke, MD, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute in Boston, talks about the strong potential of telotristat etiprate, a novel serotonin synthesis inhibitor.
Matthew H. Kulke, MD, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute in Boston, talks about the strong potential of telotristat etiprate, a novel serotonin synthesis inhibitor.
Kulke says telotristat etiprate could potentially represent a new class of treatment for patients with carcinoid syndrome, due to its ability to decrease serotonin levels. He adds that serotonin levels could present a problem for patients with carcinoid syndrome and lower levels may help avoid heart disease and fibrosis of the intestines.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
